Acarbose-induced hepatic injury

Fujimoto, Yoshinori; Ohhira, Masumi; Miyokawa, Naoyuki; Kitamori, Shigeru; Kohgo, Yutaka

doi:10.1016/s0140-6736(05)78337-9

Cited by 51 publications

(15 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Matsumoto et al maintained that voglibose most likely induced hepatitis via hypersensitivity (4). With acarbose, some physicians believe that hepatitis represents an idiosyncratic reaction (6)(7)(8)(9). In the present case, while voglibose was administered three times daily for 39 months, no allergic manifestations appeared.…”

Section: Discussionmentioning

confidence: 46%

Hepatic Necrosis with Cholestasis Induced by Long-term Voglibose Administration.

et al. 2001

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 46%

Hepatic Necrosis with Cholestasis Induced by Long-term Voglibose Administration.

et al. 2001

View full text Add to dashboard Cite

“…Several case reports from Europe and Japan have indicated that acarbose, a commonly prescribed α-glucosidase inhibitor, can result in severe, but reversible, hepatotoxicity, as indicated by markedly increased levels of AST and ALT [29–31]. In contrast, treatment with miglitol at the dosages used in the present study increased AST and ALT to a much lesser extent (≤1.8 times to upper limit of normal) [17].…”

Section: Discussionmentioning

confidence: 63%

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

et al. 2010

View full text Add to dashboard Cite

The objective of this study is to examine the efficacy and tolerability of miglitol with respect to improving glycemic control in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment. This was a randomized, double-blinded, placebo-controlled, multicenter study. A total of 105 patients were randomized to receive 24 weeks of treatment with miglitol (n = 52; titrated from 50 mg to 100 mg 3 times daily) or placebo (n = 53). Concomitant sulfonylurea treatment and diet remained unchanged. The primary endpoint was change in glycated hemoglobin (HbA1c) from baseline at 24 weeks. Secondary endpoints were changes in fasting plasma glucose (FPG), postprandial plasma glucose (PPG), and postprandial serum insulin (PSI). The miglitol treatment group showed significantly greater reductions in HbA1c and PPG levels compared with the placebo group. With respect to adverse events, abdominal discomfort, diarrhea, and hypoglycemia occurred with similar frequency in both groups. Results of this study indicate that miglitol significantly improves metabolic control in Chinese patients with type 2 diabetes mellitus. Miglitol is safe and well tolerated, with the exception of abdominal discomfort. Therefore, miglitol may be a useful adjuvant therapy for Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylurea treatment.

show abstract

“…52 Furthermore, these idiosyncratic reactions are assumed to be toxicmetabolic-dependent rather than hypersensitivity-related, because at the onset of liver injury, the patients have no symptoms of allergic reactions such as skin rash, fever, or arthralgia; the injury develops a relatively long time after the start of the drug therapy; and liver biopsy specimens show no granulomas and eosinophils. 5,52 The amount of acarbose that clearly potentiated the hepatotoxicity of CCl 4 and AP was 8 mg per rat per day, which corresponds to 21 to 22 mg/kg/d on a body-weight basis. This dose is much higher than the recommended dose for non-insulin-dependent diabetes mellitus patients (5 mg/ kg/d).…”

Section: Discussionmentioning

confidence: 99%

“…1,2 However, there are several cases of hepatic failure in patients treated with acarbose reported in the literature. [3][4][5] According to the Japan Ministry of Health and Welfare, 6 57 cases of liver dysfunction in non-insulindependent diabetes mellitus patients treated with acarbose have been reported to the Ministry (2 of these died from fulminant hepatitis).…”

mentioning

confidence: 99%

Acarbose Alone or in Combination With Ethanol Potentiates the Hepatotoxicity of Carbon Tetrachloride and Acetaminophen in Rats

et al. 1999

View full text Add to dashboard Cite

Acarbose reduces the absorption of monosaccharides derived from dietary carbohydrates, which play an important role in the metabolism and toxicity of some chemical compounds. We studied the effects of acarbose on the hepatotoxicity of carbon tetrachloride (CCl 4 ) and acetaminophen (AP) in rats, both of which exert their toxic effects through bioactivation associated with cytochrome P450 2E1 (CYP2E1). Male Sprague-Dawley rats were kept on a daily ration (

show abstract

Acarbose-induced hepatic injury

Cited by 51 publications

References 3 publications

Hepatic Necrosis with Cholestasis Induced by Long-term Voglibose Administration.

Hepatic Necrosis with Cholestasis Induced by Long-term Voglibose Administration.

Evaluation of the efficacy and tolerability of miglitol in Chinese patients with type 2 diabetes mellitus inadequately controlled by diet and sulfonylureas

Acarbose Alone or in Combination With Ethanol Potentiates the Hepatotoxicity of Carbon Tetrachloride and Acetaminophen in Rats

Contact Info

Product

Resources

About